Wyss Zurich Wyss Zurich
Wyss Zurich Wyss Zurich
Wyss Zurich
Wyss Zurich Wyss Zurich
  • About us
    • Wyss Zurich Model
    • Project Application Process
    • Overview-PDF
  • Technology Platforms
    • Regenerative Medicine Technologies
    • Robotics Technologies
  • Projects
    • Wyss Zurich projects
      • CeNeReg
      • denovoSkin
      • ETIMSred
      • hemotune
      • LifeMatrix
      • Liver4Life
      • OxyPrem
      • Seervision
      • Sevensense
      • Somagenetix
      • Voliro
    • Associate projects
      • MUS.I.C.
      • SwissProsthetics
    • Outreach projects
      • mint & pepper
      • PATHOS
    • Completed projects
      • ANYmotion
      • HYLOMORPH
      • Rosie
      • Wingtra
      • Zurich Eye
  • People
    • Leadership & Executive Team
    • Board
    • Evaluation Board
    • Faculty
    • Project-Teams
    • Platform-Teams
  • Newsroom
  • Jobs
  • Contact
  • prev
  • Search

Somagenetix

Gene therapy solutions for patients with severe inherited diseases

Gene therapy is a promising therapeutic field in medicine that is experiencing unprecedented dynamic development. Unlike the majority of drugs on the market that merely treat symptoms, this approach attempts to correct the underlying genetic cause of a disease and thereby cure patients. Somagenetix seeks to harness the power of gene therapy to develop treatments for life-threatening diseases.

The first aim is to address an inborn immunodeficiency of phagocytes, which can lead to life‐threatening bacterial and fungal infections as well as to hyperinflammation. Life expectancy in affected children and young adults is compromised and the disease burden is high. To date, the only curative option is transplantation of blood-building stem cells from donors. In the absence of a compatible donor, the patient’s own stem cells can be gene corrected. Somagenetix is developing a treatment that comprises isolation of patient stem cells from bone marrow, addition of a therapeutic gene by lentiviral vectors to compensate for the inborn genetic defect and transplantation of gene-corrected cells back into the patient.

At later phases, the aim would be to apply this platform technology to cure other monogenetic defects in various diseases of the immune system, as well as in other fields of medicine.

 

Download  Somagenetix Factsheet

 

FUNDING PARTNERS
Uniscientia Stiftung, CRPP
ImmuGene (MeF of UZH)

Share this article:
twitter-sharetwitter-sharelinkedin-sharelinkedin-sharefacebook-sharefacebook-shareemail-shareemail-share

Team

Somagenetix

Hartmann Hartmann

Guido Hartmann

Project Leader

Dabouras Dabouras

Vasilios Dabouras

Chief Regulatory Affairs Officer

Duarte Duarte

Stacy Duarte

GxP Scientist

Mathis Mathis

Simon Mathis

GMP Technician

Pastukhov Pastukhov

Oleksandr Pastukhov

Technical Project Manager and Non-Clinical Lead

Siler Siler

Ulrich Siler

Mentor

Tsapogas Tsapogas

Panagiotis Tsapogas

Scientific Associate

 

Mentors: Janine Reichenbach, Ulrich Siler



Somagenetix

News

01-04-20 - News

Wyss Zurich says thank you
read full article

12-12-19 - News

SOMAGENETIX - NEW PROJECT AT WYSS ZURICH
read more

04-12-19 - Event

Zukunftstag
read full article

01-01-70 -

Somagenetix
read full article

More News

Project description
Team
News

Wyss Zurich
ETH Zurich / University of Zurich
Weinbergstrasse 35, WEH
8092 Zurich
Switzerland

  • Newsletter
  • Media
  • Legal Disclosure
  • Photo and Video Disclaimer
  • Imprint / Disclaimer
Follow Us:
linkedin-share twitter-share instagram youtube-share
Wyss Zurich Footer Logos Wyss Zurich Footer Logos
Scroll Top Scroll Top
Download